U.S. FDA extends review of Humacyte blood vessel implant
Humacyte U.S. health regulator said it has expanded the company’s authority to test an implant that can replace a damaged or injured blood vessel, causing its shares to fall more than 15% after the close of trading.
ПОПУЛЯРНЫЕ ПОСТЫ
Poland prepares for peaking floods
Сентябрь 20, 2024
Italy evacuates thousands as Boris hits the north
Сентябрь 20, 2024
China and the US race to tame nuclear fusion for clean energy
Сентябрь 20, 2024
ПОДПИСЫВАЙТЕСЬ НА НАС
ПРЯМАЯ ТРАНСЛЯЦИЯ